Other (Income)/Deductions - Net (Parenthetical) (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended	6 Months Ended			0 Months Ended	6 Months Ended									0 Months Ended	6 Months Ended
	Jun. 29, 2014	Jun. 29, 2014	Jun. 30, 2013	Dec. 31, 2013	Oct. 31, 2013 Enbrel [Member]	Jun. 29, 2014 Neurontin [Member]	Jun. 29, 2014 Effexor [Member]	Jun. 30, 2013 Global Innovative Pharmaceutical [Member]	Jun. 30, 2013 Global Innovative Pharmaceutical [Member] In Process Research and Development [Member] compound	Jun. 30, 2013 Worldwide Research and Development Expense [Member]	Jun. 30, 2013 Consumer Healthcare [Member]	Jun. 30, 2013 Certain Investments [Member]	Jun. 30, 2013 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Sep. 06, 2012 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Feb. 06, 2013 Zoetis [Member] IPO [Member]	Jun. 29, 2014 In Process Research and Development [Member]		Jun. 29, 2014 In Process Research and Development [Member] Worldwide Research and Development Expense [Member]	Jun. 29, 2014 Insurance Settlement [Member]	Jun. 29, 2014 Distribution Rights [Member]	Jun. 29, 2014 Equity Securities [Member]	Jun. 30, 2013 Developed Technology Rights [Member] Global Innovative Pharmaceutical [Member]	Jun. 29, 2014 Litigation Settlement Payment [Member] Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. [Member]
Operating and Other Costs and Expenses [Line Items]
Royalty revenue, term					36 months
Other current assets(a)	$ 2,727	$ 2,727		$ 3,689																			$ 256
Gain on Sale of Investments																				96	98
Other legal matters, net(d)	4	698				620	55												(80)
Intangible asset impairments		$ 114	$ 489					$ 432	$ 81	$ 43	$ 14	$ 36				$ 114	[1]	$ 114				$ 394
Equity method investment, ownership percentage													49.00%	49.00%
Number of in process research and development compounds									2
Percentage offered in IPO															19.80%

[1] Reflects intangible assets written down to fair value in the first six months of 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.